Opinion|Videos|November 8, 2024
Management of Generalized Myasthenia Gravis in Pediatric Patients
Key Takeaways
- Diagnosing pediatric gMG is challenging due to its rarity and symptom overlap with other neuromuscular disorders, necessitating careful clinical evaluation.
- Standard management includes acetylcholinesterase inhibitors, corticosteroids, and immunosuppressants, customized to each patient's needs.
Panelists discuss how generalized myasthenia gravis (gMG) presents unique diagnostic challenges in pediatric populations, review current standard-of-care management strategies for children and adolescents, and highlight promising investigational treatments for pediatric gMG.
Advertisement
Video content above is prompted by the following:
- Generalized MG, although rare, can affect children and adolescents. What are the challenges in diagnosing this patient population?
- What is the standard of care for management of gMG in the pediatric population?
- Please highlight some investigational agents for pediatric gMG that you are excited about.
Advertisement
Related to this article
The approval, based on phase 3 IB1001-303 trial data showing consistent SARA scale improvement, makes levacetylleucine the first treatment approved specifically for ataxia-telangiectasia.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
A published protocol outlines the randomized, open-label EPOCH trial testing whether cilostazol accelerates hematoma resorption and improves recovery after intracerebral hemorrhage.
Brian Lin, PhD, discussed the current evidence linking football participation with ALS, the questions that remain unanswered, and how emerging research may help clarify the association.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Fokas, MD, and Minali Nigam, MD. [LISTEN TIME: 21 minutes]
A recent MS cohort study suggests that higher EBV nuclear antigen 1 antibody levels are associated with a lower risk of confirmed disability worsening, particularly among patients carrying both HLA-A02:01 and HLA-DRB115:01.
In honor of Muscular Dystrophy Awareness Month, held annually in September, NeurologyLive® looks back at the decade-long expansion of the DMD treatment landscape and the data that supports each approval.
Marketed as Fayuvi, the 1-time AAV9 gene therapy showed sustained cerebrospinal fluid heparan sulfate drops and developmental gains among pediatric patients with mucopolysaccharidosis type IIIA in prior studies.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A
2
FDA Clears Phase 1b/2 Trial of CAR T-Cell Therapy C-CAR168 for Refractory Progressive Multiple Sclerosis
3
FDA Approves Levacetylleucine for Ataxia-Telangiectasia
4
Episode 175: Advancing the Ways of Treating Cluster Headache
5